News

“Today’s ‘Last-Patient-In’ announcement is a significant milestone for our company and the NPC community,” said Chairman and CEO, N. Scott Fine. “It completes another important step in our

The acquisition is centered on a pre-clinical lead asset that complements Zealand’s focus on developing next-generation peptide therapeutics for gastrointestinal diseases. The lead asset, ET3764, is being developed

Moderna has designed mRNA-3927 to instruct the body to restore the missing or dysfunctional proteins, which cause PA. PA is a rare, life-threatening and inherited a metabolic disorder

Biotoscana is a biopharma group that operates in the Latin American region. The Brazilian company focuses on areas such as oncology and onco-hematology, infectious diseases, and other speciality

With this approval, for the first time, approximately 6,000 people with CF ages 12 years and older who have one F508del mutation and one minimal function mutation (F/MF)

This is the first pediatric approval for ULTOMIRIS. Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to

The Company expects to report top-line results from CONTESSA in the third quarter of 2020. Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class

The FDA approval was based on data from the DECLARE-TIMI 58 CV outcomes trial (CVOT). It is claimed to be the largest sodium-glucose cotransporter 2 (SGLT2) inhibitor CVOT

As per the terms of the deal, Sartorius Stedim will be acquiring Danaher’s label-free biomolecular characterization, chromatography hardware and resins, and the SoloHill business. The chromatography business is